Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility.

Kaur A, Ecker BL, Douglass SM, Kugel CH, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW, Wargo JA, Tetzlaff MT, Haydu LE, Raj A, Shenoy V, Cukierman E, Weeraratna AT.

Cancer Discov. 2018 Oct 2. pii: CD-18-0193. doi: 10.1158/2159-8290.CD-18-0193. [Epub ahead of print]

PMID:
30279173
2.

Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma.

Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00055. Epub 2018 Jun 5. No abstract available.

3.

Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease.

Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II, Davies MA.

J Neuropathol Exp Neurol. 2018 Jul 1;77(7):628-635. doi: 10.1093/jnen/nly046.

PMID:
29873738
4.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA.

Lancet Oncol. 2018 Mar;19(3):310-322. doi: 10.1016/S1470-2045(18)30078-0. Epub 2018 Feb 12.

5.

Conditional survival estimates for cancer patients.

Haydu LE, Scolyer RA, Thompson JF.

Oncotarget. 2017 Oct 4;8(49):84639-84640. doi: 10.18632/oncotarget.21497. eCollection 2017 Oct 17. No abstract available.

6.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

7.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

8.

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.

CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.

9.

Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.

An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J.

Radiother Oncol. 2017 Oct;125(1):80-88. doi: 10.1016/j.radonc.2017.08.009. Epub 2017 Sep 12.

PMID:
28916225
10.

Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes.

Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JE.

J Invest Dermatol. 2017 Aug;137(8):1792-1795. doi: 10.1016/j.jid.2017.04.007. Epub 2017 Apr 23. No abstract available.

11.

Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.

Haydu LE, Scolyer RA, Lo S, Quinn MJ, Saw RPM, Shannon KF, Spillane AJ, Stretch JR, McCarthy WH, Thompson JF.

J Clin Oncol. 2017 May 20;35(15):1721-1729. doi: 10.1200/JCO.2016.71.9393. Epub 2017 Apr 4.

PMID:
28375785
12.

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.

Kim DW, Haydu LE, Joon AY, Bassett RL Jr, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA.

Cancer. 2017 Apr 15;123(8):1372-1381. doi: 10.1002/cncr.30463. Epub 2016 Dec 2.

13.

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE.

BMC Med. 2016 Oct 25;14(1):168.

14.

Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness.

Fang S, Vaysse A, Brossard M, Wang Y, Deng D, Liu Q, Zhang P, Xu K, Li M, Feng R, Liu H, Dang Y, Chen W, Prieto V, Gershenwald JE, Ross MI, Matejka B, Malke J, Haydu LE, Reveille JD, Sui D, Bassett RL Jr, Koshkina N, Avril MF, Lu M, Wei Q, Demenais F, Amos CI, Lee JE.

J Invest Dermatol. 2017 Jan;137(1):253-257. doi: 10.1016/j.jid.2016.07.032. Epub 2016 Aug 6. No abstract available.

15.

The molecular profile of metastatic melanoma in Australia.

Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RP, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, Scolyer RA, O'Toole SA, Long GV.

Pathology. 2016 Feb;48(2):188-93. doi: 10.1016/j.pathol.2015.12.008. Epub 2016 Jan 18.

PMID:
27020391
16.

The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case-Control Study.

MacKenzie Ross AD, Haydu LE, Quinn MJ, Saw RP, Shannon KF, Spillane AJ, Stretch JR, Scolyer RA, Thompson JF.

Ann Surg Oncol. 2016 Apr;23(4):1082-9. doi: 10.1245/s10434-015-4942-0. Epub 2015 Nov 11.

PMID:
26561405
17.

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.

Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK.

EBioMedicine. 2015 May 12;2(7):671-80. doi: 10.1016/j.ebiom.2015.05.011. eCollection 2015 Jul.

18.

Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.

Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ.

Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):10995-1000. doi: 10.1073/pnas.1508074112. Epub 2015 Aug 18.

19.

Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2 mm in Thickness): Analysis of 2131 Patients Treated at a Single Center.

Haydu LE, Stollman JT, Scolyer RA, Spillane AJ, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Bonenkamp JJ, Thompson JF.

Ann Surg Oncol. 2016 Apr;23(4):1071-81. doi: 10.1245/s10434-015-4575-3. Epub 2015 May 9.

PMID:
25956574
20.

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA.

Clin Cancer Res. 2015 Jul 15;21(14):3140-8. doi: 10.1158/1078-0432.CCR-14-2023. Epub 2015 Jan 21.

21.

Sex differences in melanoma survival are not related to mitotic rate of the primary tumor.

Joosse A, van der Ploeg AP, Haydu LE, Nijsten TE, de Vries E, Scolyer RA, Eggermont AM, Coebergh JW, Thompson JF.

Ann Surg Oncol. 2015 May;22(5):1598-603. doi: 10.1245/s10434-014-4166-8. Epub 2014 Nov 19.

PMID:
25408275
22.

Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases.

Seifried S, Haydu LE, Quinn MJ, Scolyer RA, Stretch JR, Thompson JF.

Ann Surg Oncol. 2015;22(6):1959-66. doi: 10.1245/s10434-014-4215-3. Epub 2014 Nov 11.

PMID:
25384702
23.

The impact of socioeconomic status on melanoma clinical trial participation: an observational cohort study from Australia.

Lee JL, Haydu LE, Thompson JF, Morton RL.

Melanoma Manag. 2014 Nov;1(2):95-103. doi: 10.2217/mmt.14.17. Epub 2014 Dec 4.

24.

TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells.

Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, Yosufi B, Haydu LE, Mann GJ, Thompson JF, Long GV, Liu T, McArthur G, Zhang XD, Scolyer RA, Cheung BB, Marshall GM.

Oncotarget. 2014 Oct 30;5(20):10127-39.

25.

Reply to M. Perier-Muzet et al.

Zimmer L, Haydu LE, Menzies AM, Scolyer RA, Kefford RF, Thompson JF, Schadendorf D, Long GV.

J Clin Oncol. 2014 Oct 1;32(28):3203. doi: 10.1200/JCO.2014.56.8477. Epub 2014 Sep 2. No abstract available.

PMID:
25185100
26.

The optimum excision margin and regional node management for primary cutaneous T3 melanomas (2-4 mm in Thickness): a retrospective study of 1587 patients treated at a single center.

Lamboo LG, Haydu LE, Scolyer RA, Quinn MJ, Saw RP, Shannon KF, Spillane AJ, Stretch JR, Bonenkamp JJ, Thompson JF.

Ann Surg. 2014 Dec;260(6):1095-102. doi: 10.1097/SLA.0000000000000792.

PMID:
25072430
27.

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

Lee CI, Menzies AM, Haydu LE, Azer M, Clements A, Kefford RF, Long GV.

Melanoma Res. 2014 Oct;24(5):468-74. doi: 10.1097/CMR.0000000000000110.

PMID:
25054915
28.

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

Chan MM, Haydu LE, Menzies AM, Azer MW, Klein O, Lyle M, Clements A, Guminski A, Kefford RF, Long GV.

Cancer. 2014 Oct 15;120(20):3142-53. doi: 10.1002/cncr.28851. Epub 2014 Jul 1.

29.

Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible.

Fogarty GB, Hong A, Jacobsen KD, Reisse CH, Shivalingam B, Burmeister B, Haydu LE, Paton E, Thompson JF.

BMC Res Notes. 2014 Jun 30;7:412. doi: 10.1186/1756-0500-7-412.

30.

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.

Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV.

Br J Cancer. 2014 Jul 15;111(2):292-9. doi: 10.1038/bjc.2014.287. Epub 2014 Jun 10.

31.

Primary melanoma location on the scalp is an important risk factor for brain metastasis: a study of 1,687 patients with cutaneous head and neck melanomas.

Huismans AM, Haydu LE, Shannon KF, Quinn MJ, Saw RP, Spillane AJ, Stretch JR, Thompson JF.

Ann Surg Oncol. 2014 Nov;21(12):3985-91. doi: 10.1245/s10434-014-3829-9. Epub 2014 Jun 10.

PMID:
24912613
32.

Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease.

van der Ploeg AP, Haydu LE, Spillane AJ, Scolyer RA, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Thompson JF.

Ann Surg Oncol. 2014 Sep;21(9):3108-16. doi: 10.1245/s10434-014-3679-5. Epub 2014 May 7.

PMID:
24802907
33.

Pathology review significantly affects diagnosis and treatment of melanoma patients: an analysis of 5011 patients treated at a melanoma treatment center.

Niebling MG, Haydu LE, Karim RZ, Thompson JF, Scolyer RA.

Ann Surg Oncol. 2014 Jul;21(7):2245-51. doi: 10.1245/s10434-014-3682-x. Epub 2014 Apr 19.

PMID:
24748128
34.

Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.

Chien AJ, Haydu LE, Biechele TL, Kulikauskas RM, Rizos H, Kefford RF, Scolyer RA, Moon RT, Long GV.

PLoS One. 2014 Apr 14;9(4):e94748. doi: 10.1371/journal.pone.0094748. eCollection 2014.

35.

Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo confocal microscopy: new descriptors.

Guitera P, Haydu LE, Menzies SW, Scolyer RA, Hong A, Fogarty GB, Gallardo F, Segura S.

Br J Dermatol. 2014 Jun;170(6):1305-12. doi: 10.1111/bjd.12839. Epub 2014 May 22.

PMID:
24641247
36.

Outcome following sentinel node biopsy plus wide local excision versus wide local excision only for primary cutaneous melanoma: analysis of 5840 patients treated at a single institution.

van der Ploeg AP, Haydu LE, Spillane AJ, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Uren RF, Scolyer RA, Thompson JF.

Ann Surg. 2014 Jul;260(1):149-57. doi: 10.1097/SLA.0000000000000500.

PMID:
24633018
37.

Low incidence of melanoma brain metastasis in the hippocampus.

Hong AM, Suo C, Valenzuela M, Haydu LE, Jacobsen KD, Reisse CH, Fogarty G.

Radiother Oncol. 2014 Apr;111(1):59-62. doi: 10.1016/j.radonc.2014.01.012. Epub 2014 Feb 20.

PMID:
24560764
38.

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib.

Azer MW, Menzies AM, Haydu LE, Kefford RF, Long GV.

Cancer. 2014 Feb 15;120(4):530-6. doi: 10.1002/cncr.28445. Epub 2013 Nov 5.

39.

Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment.

Wilmott JS, Haydu LE, Menzies AM, Lum T, Hyman J, Thompson JF, Hersey P, Kefford RF, Scolyer RA, Long GV.

J Immunol. 2014 Mar 1;192(5):2505-13. doi: 10.4049/jimmunol.1302616. Epub 2014 Jan 31.

40.

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Rizos H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, Howle J, Saw R, Thompson JF, Kefford RF, Scolyer RA, Long GV.

Clin Cancer Res. 2014 Apr 1;20(7):1965-77. doi: 10.1158/1078-0432.CCR-13-3122. Epub 2014 Jan 24.

41.

Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients.

Kaufman KL, Mactier S, Armstrong NJ, Mallawaaratchy D, Byrne SN, Haydu LE, Jakrot V, Thompson JF, Mann GJ, Scolyer RA, Christopherson RI.

Clin Exp Metastasis. 2014 Apr;31(4):407-21. doi: 10.1007/s10585-014-9636-7. Epub 2014 Jan 17.

42.

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma.

Menzies AM, Haydu LE, Carlino MS, Azer MW, Carr PJ, Kefford RF, Long GV.

PLoS One. 2014 Jan 6;9(1):e85004. doi: 10.1371/journal.pone.0085004. eCollection 2014.

43.

A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value.

Wouters J, Stas M, Govaere O, Barrette K, Dudek A, Vankelecom H, Haydu LE, Thompson JF, Scolyer RA, van den Oord JJ.

Mod Pathol. 2014 Aug;27(8):1088-100. doi: 10.1038/modpathol.2013.228. Epub 2014 Jan 3.

44.

Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.

Zimmer L, Haydu LE, Menzies AM, Scolyer RA, Kefford RF, Thompson JF, Schadendorf D, Long GV.

J Clin Oncol. 2014 Mar 10;32(8):816-23. doi: 10.1200/JCO.2013.49.5572. Epub 2013 Dec 2.

PMID:
24297954
45.

The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients.

van der Ploeg AP, van Akkooi AC, Haydu LE, Scolyer RA, Murali R, Verhoef C, Thompson JF, Eggermont AM.

Eur J Cancer. 2014 Jan;50(1):111-20. doi: 10.1016/j.ejca.2013.08.023. Epub 2013 Sep 25.

PMID:
24074765
46.

Patterns of recurrence and survival after lymphadenectomy in melanoma patients: clarifying the effects of timing of surgery and lymph node tumor burden.

Spillane AJ, Pasquali S, Haydu LE, Thompson JF.

Ann Surg Oncol. 2014 Jan;21(1):292-9. doi: 10.1245/s10434-013-3253-6. Epub 2013 Sep 20.

PMID:
24052314
47.

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.

Dutton-Regester K, Kakavand H, Aoude LG, Stark MS, Gartside MG, Johansson P, O'Connor L, Lanagan C, Tembe V, Pupo GM, Haydu LE, Schmidt CW, Mann GJ, Thompson JF, Scolyer RA, Hayward NK.

Pigment Cell Melanoma Res. 2013 Nov;26(6):852-60. doi: 10.1111/pcmr.12153. Epub 2013 Aug 23.

PMID:
23890154
48.

Genetic and clinico-pathologic analysis of metastatic uveal melanoma.

Griewank KG, van de Nes J, Schilling B, Moll I, Sucker A, Kakavand H, Haydu LE, Asher M, Zimmer L, Hillen U, Thompson JF, Scolyer RA, Schadendorf D, Murali R.

Mod Pathol. 2014 Feb;27(2):175-83. doi: 10.1038/modpathol.2013.138. Epub 2013 Jul 26.

49.

Reproducibility of AJCC staging parameters in primary cutaneous melanoma: an analysis of 4,924 cases.

Niebling MG, Haydu LE, Karim RZ, Thompson JF, Scolyer RA.

Ann Surg Oncol. 2013 Nov;20(12):3969-75. doi: 10.1245/s10434-013-3092-5. Epub 2013 Jul 13.

PMID:
23851608
50.

Margins of excision and prognostic factors for cutaneous eyelid melanomas.

Harish V, Bond JS, Scolyer RA, Haydu LE, Saw RP, Quinn MJ, Benger RS, Uren RF, Stretch JR, Shannon KF, Thompson JF.

J Plast Reconstr Aesthet Surg. 2013 Aug;66(8):1066-73. doi: 10.1016/j.bjps.2013.04.032. Epub 2013 May 17.

PMID:
23688975

Supplemental Content

Loading ...
Support Center